Horizon Discovery Group plc appoints Mr Grahame Cook as a Non-Executive Director

Cambridge, UK, 14 May 2014: Horizon Discovery Group plc (LSE:HZD), the international life science company supplying research tools and services that power genomics research and the development of personalised medicines, today announces the appointment of Mr Grahame Cook as a Non-Executive Director of the Board with immediate effect. Grahame has also been appointed to the Audit Committee, within which he will assume the role of Chairman.

Grahame Cook is an experienced FTSE and AIM non-executive, with extensive experience as an audit committee chairman. With a background in banking, where he has specialised in the life sciences, pharma and biotech sectors, Grahame has over 20 years’ experience of M&A, equity capital markets and investor relations.

Grahame started his career at Arthur Andersen, where he qualified as a chartered accountant and worked within audit and corporate investigations. Subsequent positions include UBS, where he was a member of the global investment banking management committee and global head of equity advisory, and WestLB Panmure, where he was joint Chief Executive Officer. Grahame currently sits on a number of boards, chairing four, including Sinclair Pharma plc and Morphogenesis Inc.

Grahame is a graduate of the University of Oxford and remains a member of the ICAEW. 

Dr. Ian Gilham, Chairman of Horizon’s Board of Directors, commented: “I would like to welcome Grahame to Horizon’s Board and I am confident that Grahame’s significant financial and audit experience in growth-oriented life sciences companies and track record in international capital markets, corporate transactions and strategy-setting will prove to be highly valuable as Horizon continues to grow internationally in fast growing markets.

Mr. Grahame Cook said: “Horizon is an outstanding, innovative company which is becoming a global leader in translational and personalised medicine. I am pleased to join an exceptional board of directors guiding the Company during this important time in its evolution.”

http://www.onenucleus.com/news?id=4975

 

Leave a Reply